DF/HCC: 17-540 (Non-Small Cell Lung Cancer) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if a combination of the study drugs, Osimertinib and Selumetinib, are safe and will work in treating Non-Small Cell Lung Cancer (NSCLC) with a gene mutation.

What is the Condition Being Studied?

Non-Small Cell Lung Cancer (NSCLC)

Who Can Participate in the Study?

Adults who have stage IV NSCLC with EGFR mutation.

Age Group

What is Involved?

If you choose to join this study, you will:
- Get study drugs Osimertinib and Selumetinib
-- You will take Osimertinib once a day every day and Selumetinib twice a day for 4 days
- Have routine eye exams
- Have blood samples and possibly a small piece of tissue removed from your lung to see what type of lung cancer cells you have
- Have other tests, exams, and procedures for study purposes and your standard of care
- Be in the study until your condition worsens or you have unbearable side effects

Study Details

Full Title
A Phase 2 Study of osimertinib in combination with selumetinib in EGFR inhibitor naive advanced EGFR mutant lung cancer
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00090252
NCT: NCT03392246
Phase II
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center